Physician profile
James S Hoff
NPI 1598859654
$27,302.62
in general payments reported to CMS, 2019-2025
72 companies · $24.88 in 2025
The $24.88 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,732 · 2020: $4,496 · 2021: $5,564 · 2022: $4,444 · 2023: $3,991 · 2024: $3,050 · 2025: $24.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,866 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,865.94 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,066.06 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $2,329.53 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $2,314.76 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $2,287.51 | 2019-2024 | |
| Lilly USA, LLC | $1,561.38 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,527.61 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,392.04 | 2019-2025 | Xarelto, Spravato |
| Kowa Pharmaceuticals America, INC. | $949.52 | 2019-2023 | Livalo, Seglentis |
| Boston Scientific Corporation | $938.05 | 2019-2020 | |
| Pfizer INC. | $924.32 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $747.31 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $738.53 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $724.23 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $696.03 | 2019-2024 | Xifaxan |
| Allergan, INC. | $640.43 | 2019-2020 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.